Seventy years have passed since Minamata disease—a severe form of mercury poisoning—was officially confirmed in Japan. To mark the occasion, medical experts and social activists are stressing the urgent need for a comprehensive, large-scale study into fetal Minamata disease.
First documented in Minamata Bay, Kumamoto Prefecture, in 1956, the disease was caused by the Chisso chemical plant discharging methylmercury into the marine environment. The toxin accumulated in fish and shellfish, poisoning local residents who consumed them. The fetal form occurs when a fetus is exposed to mercury through the placenta, leading to severe congenital abnormalities, irreversible neurological damage, and developmental delays.
According to experts, despite seven decades, the long-term effects of the fetal form remain poorly understood. “A thorough study is a prerequisite for accurately assessing the aftermath, and thus for developing appropriate medical and social policies to support patients and their families,” noted a public health specialist.
Today, many fetal-form patients are middle-aged or elderly, facing complex health issues. Scientists believe that data from new research could shed light on the genetic mechanisms and late-onset manifestations of the disease, while also helping to establish long-term care programs.
The push for a comprehensive study comes amid ongoing debate in Japan over compensation and environmental remediation related to the Minamata disaster. Current efforts include periodic health monitoring for victims, but experts say a strategic, nationwide research plan is still needed to fully resolve the unknowns surrounding fetal Minamata disease.
Data from Japan’s Ministry of the Environment shows that as of the end of 2023, more than 2,200 people had been officially recognized as Minamata patients (including the fetal form). However, the estimated number of affected individuals is much higher, due to diagnostic criteria and incomplete documentation in the early years.
